AstraZeneca (AZN) Announces Restructuring, Will Eliminate 7,300 Positions
AstraZeneca (NYSE: AZN) announced new restructuring initiatives designed to improve productivity and strengthen the company’s commercial, operations and research and development capabilities.
This new program is expected to deliver an estimated $1.6 billion in annual benefits by the end of 2014, at an estimated total cost of $2.1 billion. AstraZeneca expects that this restructuring program will affect approximately 7,300 positions. Final estimates for program costs, benefits and headcount impact in all areas of the business are subject to completion of applicable consultation processes.
Within AstraZeneca’s SG&A category – which encompasses corporate and support functions as well as the commercial organisation – the company will continue to drive efficiencies, rationalise non-customer facing support groups and introduce new ways of meeting customer needs.
One change already under way is the simplification of the company’s global commercial organisation structure. The number of sales and marketing regions has been reduced from five to three and smaller countries are being clustered, a move that will optimise resources, increase shared services and reduce the cost base.
In parallel, AstraZeneca is accelerating its use of new customer channels providing innovative, high quality services that better meet the changing needs of healthcare professionals at lower unit costs. These new channels – which include digital technology and the use of call centres for sales and medical advice – have been successfully established in many developed markets and are now being deployed around the world.
The company currently estimates that approximately 3,750 positions will be affected by the programme spanning SG&A. (Emphasis ours.)
The R&D function will accelerate its transformation, which the company unveiled in January 2010. Under the new programme announced today, further changes will create a simpler and more innovative R&D organization with a lower and more flexible cost base. Excess capacity in certain R&D functions will be reduced, matching resources to AstraZeneca’s more focused R&D portfolio.
A focus for much of the change in R&D is the neuroscience therapy area. While the patient need for better medicines in neuroscience is huge and the science is promising, advances in treatments have proved elusive for the pharmaceutical industry in recent years, despite significant investment. AstraZeneca believes that it will have the best chance of success in future by combining the company’s internal expertise with innovative external science.
As a result, AstraZeneca will create a new “virtual” neuroscience Innovative Medicines unit (iMed) made up of a small team of around 40 to 50 AstraZeneca scientists conducting discovery and development externally, through a network of some of the most innovative partners in academia and industry globally. The team will be based in major neuroscience hubs – Boston (US) and Cambridge (UK) – and work closely with innovative partners such as the Karolinska Institute in Stockholm (Sweden).
In recent years, AstraZeneca has made a number of strategic changes to improve the efficiency and effectiveness of its supply chain and outsource some manufacturing activity, particularly the production of active pharmaceutical ingredients. The new programme will drive further efficiency in the supply chain, with a particular focus on support functions in Operations.
Total positions affected within the company’s Operations function are estimated to be around 1,350. (Emphasis ours.)
Get immediate access to market moving news and alerts with StreetInsider.com Premium - FREE TRIAL!
This new program is expected to deliver an estimated $1.6 billion in annual benefits by the end of 2014, at an estimated total cost of $2.1 billion. AstraZeneca expects that this restructuring program will affect approximately 7,300 positions. Final estimates for program costs, benefits and headcount impact in all areas of the business are subject to completion of applicable consultation processes.
Within AstraZeneca’s SG&A category – which encompasses corporate and support functions as well as the commercial organisation – the company will continue to drive efficiencies, rationalise non-customer facing support groups and introduce new ways of meeting customer needs.
One change already under way is the simplification of the company’s global commercial organisation structure. The number of sales and marketing regions has been reduced from five to three and smaller countries are being clustered, a move that will optimise resources, increase shared services and reduce the cost base.
In parallel, AstraZeneca is accelerating its use of new customer channels providing innovative, high quality services that better meet the changing needs of healthcare professionals at lower unit costs. These new channels – which include digital technology and the use of call centres for sales and medical advice – have been successfully established in many developed markets and are now being deployed around the world.
The company currently estimates that approximately 3,750 positions will be affected by the programme spanning SG&A. (Emphasis ours.)
The R&D function will accelerate its transformation, which the company unveiled in January 2010. Under the new programme announced today, further changes will create a simpler and more innovative R&D organization with a lower and more flexible cost base. Excess capacity in certain R&D functions will be reduced, matching resources to AstraZeneca’s more focused R&D portfolio.
A focus for much of the change in R&D is the neuroscience therapy area. While the patient need for better medicines in neuroscience is huge and the science is promising, advances in treatments have proved elusive for the pharmaceutical industry in recent years, despite significant investment. AstraZeneca believes that it will have the best chance of success in future by combining the company’s internal expertise with innovative external science.
As a result, AstraZeneca will create a new “virtual” neuroscience Innovative Medicines unit (iMed) made up of a small team of around 40 to 50 AstraZeneca scientists conducting discovery and development externally, through a network of some of the most innovative partners in academia and industry globally. The team will be based in major neuroscience hubs – Boston (US) and Cambridge (UK) – and work closely with innovative partners such as the Karolinska Institute in Stockholm (Sweden).
In recent years, AstraZeneca has made a number of strategic changes to improve the efficiency and effectiveness of its supply chain and outsource some manufacturing activity, particularly the production of active pharmaceutical ingredients. The new programme will drive further efficiency in the supply chain, with a particular focus on support functions in Operations.
Total positions affected within the company’s Operations function are estimated to be around 1,350. (Emphasis ours.)
Get immediate access to market moving news and alerts with StreetInsider.com Premium - FREE TRIAL!
You May Also Be Interested In
- Royalty Pharma Raises $600 Million of Debt
- McCarter & English Continues to Expand Its Patent Litigation Practice with the Addition of Thomas A. Stevens in Wilmington
- Rue21, Inc. (RUE) Tops Q1 EPS by 3c; Boosts FY12 EPS Outlook; Approves $50M Buyback
Create E-mail Alert Related Categories
Corporate News, GuidanceSign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!
